scholarly journals Burden of High Disease Activity in Systemic Lupus Erythematosus (SLE): Results of A Targeted Literature Review

2017 ◽  
Vol 20 (9) ◽  
pp. A544
Author(s):  
R Tan ◽  
K Adamski ◽  
E Tuttle ◽  
O Guenther ◽  
C Henke
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Literature Review ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
High Disease Activity ◽  
Systemic Lupus

Clinical, neuroimaging and immunological phenotype of South African neuropsychiatric systemic lupus erythematosus patients

Lupus ◽  
2019 ◽  
Vol 28 (5) ◽  
pp. 685-694
Author(s):  
N Mvambo ◽  
A I Bhigjee ◽  
G M Mody
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cerebrovascular Disease ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Large Vessel ◽  
High Disease Activity ◽  
Small Vessel ◽  
Systemic Lupus ◽  
Vessel Disease ◽  
Large Vessel Disease

Neuropsychiatric systemic lupus erythematosus (NPSLE) is an important cause of morbidity and mortality. We undertook this observational retrospective study of patients with NPSLE who had brain magnetic resonance imaging (MRI) to determine the indications for MRI and the correlation of clinical and laboratory findings with MRI. We identified 83 NPSLE patients (84.3% women) seen at Inkosi Albert Luthuli Central Hospital in Durban, South Africa, between June 2003 and May 2017. The mean age at SLE diagnosis was 26.24 ± 12.81 years and the median interval to NPSLE was 11.0 (interquartile range, 4.0–39.0) months. The most common indications for MRI were seizures (45.8%), psychosis (18.1%) and cerebrovascular disease (18.1%). The MRI was abnormal in 68 (81.9%) with small-vessel disease in 65 (78.3%) and large-vessel disease in eight (9.6%). The small-vessel abnormalities were white-matter hyperintensities (WMH) (59.0%), atrophy (55.4%) and lacunae (4.6%). Our patients had high disease activity at NPSLE. Cerebrovascular disease was associated with an abnormal MRI ( p = 0.018) and large-vessel disease ( p = 0.014) on MRI. Our NPSLE patients were younger and had high disease activity, and seizures were more common compared with other studies. The most common MRI abnormalities were WMH and cortical atrophy, in agreement with other studies.

scholarly journals Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis

Rheumatology ◽  
2016 ◽  
Vol 55 (9) ◽  
pp. 1664-1672 ◽  
Author(s):  
Mathilde Pugès ◽  
Pascal Biscay ◽  
Thomas Barnetche ◽  
Marie-Élise Truchetet ◽  
Christophe Richez ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Literature Review ◽  
Disease Activity ◽  
Systematic Literature Review ◽  
Lupus Erythematosus ◽  
Meta Analysis ◽  
Pneumococcal Vaccines ◽  
Systemic Lupus

scholarly journals High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus

2020 ◽  
Vol 7 (1) ◽  
pp. e000372
Author(s):  
Rachel Koelmeyer ◽  
Hieu Tri Nim ◽  
Mandana Nikpour ◽  
Ying B Sun ◽  
Amy Kao ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Disease Severity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Severe Disease ◽  
High Disease Activity ◽  
Physician Global Assessment ◽  
Systemic Lupus ◽  
Damage Accrual

ObjectiveDisease severity in SLE is an important concept related to disease activity, treatment burden and prognosis. We set out to evaluate if high disease activity status (HDAS), based on ever attainment of a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) disease activity score of ≥10, is an indicator for disease severity in SLE.MethodsUsing prospectively collected data, we assessed the association of HDAS with sociodemographic and disease characteristics and adverse clinical outcomes using logistic regression or generalised estimating equations.ResultsOf 286 patients with SLE, who were observed for a median (range) of 5.1 years (1–10.8 years), 43.7% experienced HDAS at least once during the observational period. Autoantibody positivity, particularly anti-dsDNA and anti-Sm positivity, were associated with increased likelihood of HDAS. Age ≥45 years at diagnosis was associated with reduced likelihood of HDAS (p=0.002). Patients with HDAS had higher Physician Global Assessment score (>1: OR 8.1, p<0.001) and were more likely to meet criteria for flare (mild/moderate flare: OR 4.4, p<0.001; severe flare: OR 17.2, p<0.001) at the time of experiencing HDAS. They were also more likely to have overall higher disease activity, as defined by time-adjusted mean SLEDAI-2K score in the highest quartile (OR 11.7, 95% CI 5.1 to 26.6; p>0.001), higher corticosteroid exposure (corticosteroid dose in highest quartile: OR 7.7, 95% CI 3.9 to 15.3; p<0.001) and damage accrual (OR 2.3, 95% CI 1.3 to 3.9; p=0.003) when compared with non-HDAS patients.ConclusionsHDAS is associated with more severe disease, as measured by higher disease activity across time, corticosteroid exposure and damage accrual. The occurrence of HDAS may be a useful prognostic marker in the management of SLE.

Sign in / Sign up

Export Citation Format

Share Document